Next year is gearing up for anticipated regulatory movement in the uveitic macular edema (UME) space. Why, you ask? One word: vamibikart.
Following Roche’s latest phase 3 data readout during the American Academy of Ophthalmology (AAO) 2026 annual meeting, this late-stage candidate is proving to be a leading contender in becoming the first purpose-built therapeutic to target this common disease impacting 8% of uveitis patients.
Let’s start with the basics: current UME treatments.
While several FDA-approved drugs on the market are already utilized for UME management, they share a common theme:
- primarily corticosteroid-based as intravitreal (IVT) implants or systemic biologics
- while approved for uveitis, they’re not specifically labeled for UME
- In other words: They’re all broad anti-inflammatory therapies
Prime examples of these include AbbVie’s Ozurdex, a corticosteroid IVT implant indicated for noninfectious uveitis (NIU) affecting the posterior segment, as well as fluocinolone acetonide IVT implants like Bausch + Lomb’s Retisert; and AbbVie’s adalimumab (Humira), a systemic therapy.
So as far as an UME-targeted therapeutic goes …
The FDA has yet to approve a drug specifically labeled to only treat UME—not to mention a steroid-free option to boot.
And that’s where Roche’s candidate comes in, right?
Correct. Vamikibart is an investigational monoclonal antibody specifically engineered for IVT administration.
- What it targets: interleukin-6 (IL-6)—an inflammatory protein (cytokine) involved in the inflammatory pathway in UME—to stop it from signaling through its receptor.
- The intended result: reduced inflammation that leads to reduced fluid building up in the macula.
Also worth noting: As this therapy is IVT-administered (inside the eye), it’s unique from systemic IL-6 blockade such as Roche’s tocilizumab (Actemra), which is already used off-label in UME.
Noted. And its current clinical status?
Roche submitted a Biologics License Application (BLA) for the therapy’s UME indication, which—based on the company’s Oct. 10 update—the FDA has accepted for review.
The federal agency is expected to make a decision for potential approval by July 2027.
Wow. So what clinical data was this BLA package based on?
Results from two now-completed multicenter, randomized, double-masked, sham-controlled phase 3 studies (which are, coincidentally, also the subject of this newest data readout):
- MEERKAT (NCT05642312)
- SANDCAT (NCT05642325)
And how has vamikibart performed thus far?
Before we discuss its phase 3 performance, the therapy was previously evaluated in DOVETAIL (NCT06771271), an open-label, nonrandomized phase 1 trial.
Its purpose: to evaluate the safety, tolerability, and effects of an IVT-administered vamikibart (in three doses) among patients with UME secondary to noninfectious uveitis (NIU) over a 12-week period.
The crux of that data: Vamikibart resulted in:
- Rapid vision gains (improvements in best-corrected visual acuity [BCVA] and central subfield thickness [CST]) across all three doses
- Resolution of macular edema
- No treatment-related serious adverse events (AEs)
See here for more.
Next up: these phase 3 trials.
Before we talk data, a quick rundown on their identical setups:
- Participants: 245 (MEERKAT), 256 (SANDCAT) diagnosed with macular edema associated with NIU
- Design: patients randomized to receive treatment every 4 weeks (QID)—for up to 16 weeks—of three optional doses (See below) followed by PRN treatment through week 52:
- 0.25 mg vamikibart
- 1 mg vamikibart
- Sham IVT injection
- Outcome measures:
- Primary: patients with a +15-letter improvement from baseline in BCVA at week 16
- Secondary: average change from baseline in BCVA and CST at week 16
- To note: Safety was assessed via AEs (treatment-related ocular AEs, intraocular inflammation (IOI), and retinal occlusive vasculitis
Alrighty, now to this new data.
We’ll start broadly: Across both studies, vamikibart “demonstrated sustained improvements in vision and reductions in macular thickness” among UME patients at 52 weeks.
Regarding the shared primary goal: A “numerically higher proportion” of vamikibart-treated patients achieved vision gains versus sham treatment.
How about those secondary outcomes?
The benefits from those vision gains were also reportedly maintained, with "sustained improvements in average change from baseline” in both BCVA and CST.
And just how durable were its clinical benefits?
A low treatment burden was evident, with an estimated 66% (two-thirds) of eligible patients (a specific number was not provided), requiring no retreatment after 16 weeks.
As for the majority of those who did require additional treatment: that number was limited to just one injection.
Talk safety.
Not only was vamikibart well tolerated and maintained a favorable safety profile, but it did so with a low incidence of treatment-related ocular AEs and IOI events.
So how does this 1-year data compare to last year’s data readout?
Roche’s previous reporting (during AAO 2025) was based on 16-week data. Those numbers were released in full—with mixed results:
- MEERKAT: met the primary endpoint (+19.9% and +36.9% vs sham)
- Mean BCVA change: +9.6 and +12.8 letters vs sham
- CST change: about −188 to −196 µm vs −58.5 sham.
- SANDCAT: missed the primary endpoint (+20.7% nominal; +10.9%, p = 0.0699)
- Mean BCVA change: +11.9 and +9.2 vs +5.0 (not significant)
- CST change: about −195 to −210 µm vs −43.5 (not significant)
See here for more from that 2025 data readout.
Lastly: What’s the big picture of vamikibart for UME?
If the FDA approves its BLA, the therapy would become the first non-steroid targeted treatment for UME, "with the potential to establish a new standard of care,” according to Roche.